Efficacy And Safety Of A Cxcr2 Antagonist, Azd5069, In Severe, Uncontrolled Persistent Asthma

被引：0
|
作者：
O'Byrne, P. M. [1 ]
Metev, H. [2 ]
Puu, M. [3 ]
Richter, K. [3 ]
Keen, C. [3 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] SHATPPD Ruse EOOD, Ruse, Bulgaria
[3] AstraZeneca R&D, Molndal, Sweden
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2503
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis
    Pavord, Ian
    De Soyza, Anthony
    Elborn, J. Stuart
    Smith, David
    Wray, Heather
    Puu, Margareta
    Larsson, Bengt
    Stockley, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [2] Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
    O'Byrne, Paul M.
    Metev, Hristo
    Puu, Margareta
    Richter, Kai
    Keen, Christina
    Uddin, Mohib
    Larsson, Bengt
    Cullberg, Marie
    Nair, Parameswaran
    LANCET RESPIRATORY MEDICINE, 2016, 4 (10): : 797 - 806
  • [3] Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma
    Watz, Henrik
    Uddin, Mohib
    Pedersen, Frauke
    Kirsten, Anne
    Goldmann, Torsten
    Stellmacher, Florian
    Groth, Espen
    Larsson, Bengt
    Bottcher, Gerhard
    Malmgren, Anna
    Kraan, Maarten
    Rabe, Klaus F.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 : 121 - 123
  • [4] Synthesis of isotopomers of AZD5069, a potent CXCR2 antagonist
    Hickey, Mike J.
    Hansen, Peter
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2015, 58 (04): : 155 - 155
  • [5] The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD
    Kirsten, A. M.
    Foerster, K.
    Radeczky, E.
    Linnhoff, A.
    Balint, B.
    Watz, H.
    Wray, H.
    Salkeld, L.
    Cullberg, M.
    Larsson, B.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 31 : 36 - 41
  • [6] The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers
    Lorch, Ulrike
    Negi, Hedigo
    Tabata, Hirobumi
    Wray, Heather
    Cullberg, Marie
    Larsson, Bengt
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [7] A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis
    De Soyza, Anthony
    Pavord, Ian
    Elborn, J. Stuart
    Smith, David
    Wray, Heather
    Puu, Margareta
    Larsson, Bengt
    Stockley, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (04) : 1021 - 1032
  • [8] Syntheses of a radiolabelled CXCR2 antagonist AZD5069 and its major human metabolite
    Hickey, Michael J.
    Allen, Paul H.
    Caffrey, Moya
    Hansen, Peter
    Kingston, Lee P.
    Wilkinson, David J.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2016, 59 (11): : 432 - 438
  • [9] The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
    Kirsten, Anne Marie
    Forster, Karin
    Radeczky, Eva
    Linnhoff, Anneliese
    Balint, Beatrix
    Watz, Henrik
    Wray, Heather
    Salkeld, Lynette
    Cullberg, Marie
    Lam, Hung
    Larsson, Bengt
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [10] Evidence on the identity of the CXCR2 antagonist AZD-5069
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (01) : 113 - 117
12345